iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
ViiV HEALTHCARE TO SHOWCASE INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT IDWEEK™ AND HIV GLASGOW
 
 
  Download the PDF here
 
More than 50 abstracts at the two scientific congresses will showcase new mechanisms of action, implementation of the only complete long-acting treatment regimen and key insights into real-world treatment outcomes
 
London, 12 October 2022 - ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of over 50 abstracts from the company's diverse portfolio of innovative licensed treatment and prevention options at IDWeek™ 2022, being held in Washington, D.C., from 19 - 23 October and at HIV Glasgow taking place between 23 - 26 October 2022 in Glasgow, Scotland.
 
Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: "As the only pharmaceutical company solely focused on HIV, we're excited to share our pioneering research findings at IDWeek™ and HIV Glasgow that are focused on helping to address the evolving needs of those impacted by HIV. Presentations will showcase our continued innovation across both HIV treatment and prevention, and include first-time findings from our early pipeline as well as implementation data and real-world evidence from our established treatment portfolio. We look forward to joining scientific leaders from around the world to advance the collective understanding of HIV and promote new solutions to care together."
 
Advancing innovation in HIV research
At HIV Glasgow, ViiV Healthcare will be sharing findings from the BANNER study, a phase IIa proof-of-concept study of N6LS (VH3810109), a novel, investigational, broadly neutralising antibody (bNAb) that is being investigated in adults living with HIV at two dosing levels - a high dose and ten-fold lower dose (40 mg/kg and ∼4 mg/kg (280 mg)), respectively. N6LS works by binding to a specific site (gp120) on the surface of HIV that prevents its entry into immune system cells (CD4+ T-cells). By blocking HIV's entry into human CD4+ cells, the virus is unable to replicate, and the HIV transmission process may be prevented. Researchers will share the proof-of-concept findings evaluating the safety, pharmacokinetics, and antiviral activity of a single IV infusion of N6LS in treatment-na├»ve people living with HIV.1
 
Data from the HPTN 083 study will also be presented at HIV Glasgow, providing further analysis of the efficacy of Apretude (cabotegravir long-acting) for pre-exposure prophylaxis (PrEP) in men who have sex with men and transgender women in the first year after unblinding the study.2
 
Implementing long-acting treatment in a clinical setting
ViiV Healthcare will share results from its pioneering implementation science program that aims to identify successful methods of integrating its medicines for HIV treatment in the clinical setting. The CARISEL study evaluates the best approaches to implementing Vocabria/Rekambys (cabotegravir, rilpivirine; marketed as Cabenuva in the US) administered every two months into clinical practice in Europe. Clinical results will be presented at IDWeek™ followed by primary results of the study at HIV Glasgow. Data to be presented include efficacy and safety results, implementation outcomes and people living with HIV, healthcare professionals and staff preferences in a number of European clinics, through different implementation strategies across a diverse (gender, race and age) population living with HIV.3
 
Additionally, patient-reported outcomes from the phase IIIb ATLAS-2M study of virologically suppressed adults living with HIV-1 following 152 weeks of HIV maintenance therapy with CAB + RPV LA will be presented at HIV Glasgow. Participants shared details of treatment satisfaction, preferences, and acceptability of injections.4
 
Establishing real-world evidence for 2-drug and long-acting regimens
Real-world evidence, which is data derived from studies fielded in a real-world setting, can provide a fuller understanding of a therapy, how it works in clinical practice, and how to address the evolving needs of people living with HIV. ViiV Healthcare will present findings from real-world studies of its HIV therapies as an essential tool to help bridge the gap between clinical trials and clinical practice.
 
Data from the OPERA cohort to be presented at IDWeek™ compare real-world safety and effectiveness data in virologically suppressed adults taking Dovato (dolutegravir, lamivudine) with those taking a bictegravir- or dolutegravir-based 3-drug regimen.5 ViiV Healthcare will also be presenting six-month implementation results from the CARLOS study at HIV Glasgow investigating effectiveness, adherence and patient reported outcomes alongside provider perceptions following the integration of CAB + RPV LA in German clinics.6,7 Additional data from the BEYOND study of CAB + RPV LA provide further insights into US physician perceptions on administration and implementation of the long-acting therapy in their practice will be presented at IDWeek™.8
 
Here is a list of ViiV Healthcare and partner study data to be presented at IDWeek™ and HIV Glasgow:

1012221

1012222

1012223

1012224

1012225

1012226

1012227

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org